BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• 

  Regulatory

  FDA asks 2,200 drug developers to make trial results public, ramping up transparency push

  Some 30% of clinical trials that are mandated to report their findings have not posted results to clinicaltrials.gov, the federal government’s public repository for studies, according to internal data from the FDA.

  April 14, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  On steadier ground, pharma heads into Q1 earnings with deals top of mind

  During the pharma earnings season, which begins on Tuesday, Novo Nordisk will report the first revenue numbers from an oral GLP-1 medicine, while other companies are expected to address the FDA, drug pricing and Trump’s new tariffs.

  April 14, 2026

   · 

  5 min read

   · 

  Annalee Armstrong
• 

  Approvals

  Travere’s Filspari overcomes Phase 3 fail to become first drug for rare kidney disease

  The FDA has greenlit Travere Therapeutics’ Filspari as the only available treatment for focal segmental glomerulosclerosis despite the drug’s loss to Sanofi’s Avapro in a Phase 3 study.

  April 14, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Opinion

  Adopting a patient-centric approach is a competitive advantage

  Bringing patients into the drug development process early has proven to save time, money and resources.

  April 14, 2026

   · 

  4 min read

   · 

  Charlotte Moser
• 

  Manufacturing

  Lilly investing billions to prepare for overseas oral GLP-1 launches

  With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 countries and is building manufacturing capacity to support the obesity drug.

  April 14, 2026

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Mergers & acquisitions

  Lilly wants to bridge cancer care gap with $300M ADC biotech buy

  Eli Lilly is putting its obesity windfall to work again, striking a new deal to acquire CrossBridge Bio, a small Texas biotech known for its cancer tech.

  April 14, 2026

   · 

  1 min read

   · 

  Gabrielle Masson
• 

  Earnings

  With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026

  With robust sales performance from oncology darling Darzalex and immunology superstar Tremfya, Johnson & Johnson is “off to a fast start in 2026,” CEO Joaquin Duato told investors on Tuesday.

  April 14, 2026

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Job Trends

  Bonus: Q1 2026 Job Market Update

  In this bonus episode, BioSpace’s Vice President of Marketing ⁠Chantal Dresner⁠ and Careers Editor ⁠Angela Gabriel⁠ take a look at Q1 job market performance and what it signals for the coming months.

  April 14, 2026

   · 

  1 min read

   · 

  Angela Gabriel
• 

  Gene editing

  FDA bolsters bespoke therapy framework with new draft safety guidelines

  The draft guidance supports the agency’s new pathway designed to speed up the development of custom gene therapies.

  April 14, 2026

   · 

  2 min read

   · 

  Gabrielle Masson
• 

  Layoffs

  50 employees impacted as Astellas closes Universal Cells’ Seattle office

  By closing the Universal Cells Seattle location, Astellas is reportedly consolidating cell therapy, gene therapy and oncology research at its South San Francisco, California, and Westborough, Massachusetts, sites.

  April 14, 2026

   · 

  2 min read

   · 

  Angela Gabriel